University of Melbourne

SARS-CoV-2 vaccination creates a strong, persistent T-cell response

Retrieved on: 
Giovedì, Dicembre 23, 2021
Blood, University of Melbourne, Center, Vaccination, University of Rochester Medical Center, Omicron, St. Jude Children's Research Hospital, NCI-designated Cancer Center, Immunity, NHMRC, National, Washington University in St. Louis, ALSAC, University, Survival, National Institute of Allergy and Infectious Diseases, COVID-19, Research, Australian Research Council, Hospital, National Cancer Center, Immune system, Awareness, Child, Lymph, Social media, Monash University, Severe acute respiratory syndrome coronavirus 2, CD4, Multimedia, National Institute, National Cancer Institute, Excellence, Influenza research, Infection, Contract, Vaccine, Jude the Apostle, Cell

The findings suggest that some aspects of the immune response to mRNA vaccines remain robust six months after vaccination.

Key Points: 
  • The findings suggest that some aspects of the immune response to mRNA vaccines remain robust six months after vaccination.
  • Much of the research on immune response to mRNA vaccination has focused on antibody levels, which can be measured by a blood test.
  • Researchers wanted to better understand the specificity and structure of the T-cell response to vaccination.
  • The cohort was established in 2020 with hospital St. Jude employees who volunteered to have their immune response to SARS-CoV-2 infection and vaccination monitored.

PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions

Retrieved on: 
Mercoledì, Dicembre 8, 2021
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Research, SEC, LSE, Technology, Therapy, Annual general meeting, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Safety, Allopregnanolone, Control, Private Securities Litigation Reform Act, GABAA, BIG, Cancer, Brain, Axis, Liver, Journal, Lymphatic system, Fat, PK, Epilepsy, American College, Depression, Epileptic Disorders, Sleep, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.

Key Points: 
  • Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.
  • The data presented at ACNP showed that systemic exposure of natural allopregnanolone was achieved after oral administration of LYT-300 in multiple preclinical models of increasing complexity.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions

Retrieved on: 
Martedì, Dicembre 7, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sleep, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Lists of diseases, Research, SEC, LSE, Technology, Therapy, Pharmacokinetics, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Allopregnanolone, Safety, Control, GABAA, BIG, Cancer, Brain, Axis, Private Securities Litigation Reform Act, Liver, Food, Journal, Lymphatic system, Fat, PK, Epilepsy, Depression, Epileptic Disorders, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.

Key Points: 
  • LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.
  • Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

Comprehensive Glycoscience Encyclopedia Edition No. 2, 5 Volume Set (2021) - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 25, 2021
Science, Health, Other Science, Other Health, Volume, National Centre for Foreign Animal Disease, University, University of Melbourne, French National Centre for Scientific Research, University of Alberta, Technology, Center, Research, Edition, CNRS, Interaction, Scientific method, Pharmaceutical industry

Comprehensive Glycoscience, Second Edition, Five Volume Set assembles the top minds in this area who provide an update on the renowned 2007 first edition, including new discoveries and latest advances in glycoscience-related research areas such as glycan microarrays, carbohydrate materials, glycoengineering and microbiome research.

Key Points: 
  • Comprehensive Glycoscience, Second Edition, Five Volume Set assembles the top minds in this area who provide an update on the renowned 2007 first edition, including new discoveries and latest advances in glycoscience-related research areas such as glycan microarrays, carbohydrate materials, glycoengineering and microbiome research.
  • The result is an up-to-date work which will impress readers with the many new advances that are outlined and taught in this second edition.
  • Introduction to Glycoscience, Glycan Structure and Function Joseph J. Barchi, Jr., Center for Cancer Research, Frederick, MD, USA
    2.
  • Glycans in Development, Health and Disease Professor Naoyuki Taniguchi, Osaka International Cancer Institute, Japan
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006068/en/

Foot Locker, Inc. Announces Organizational Enhancements To Advance Long-Term Global Growth And Power Omni-Channel Ecosystem

Retrieved on: 
Giovedì, Novembre 18, 2021
Senior, Judgement, University of Melbourne, Risk, Annual report, Company, NYSE, Foot Locker, VP, University, History, Development, Nike, Inc., WSS, Heart, General officer, Canada, General manager, BBA, Marketing, Fashion merchandising, Brand management, Glasgow Caledonian University, Loblaw Companies, Champs Sports, Public expenditure, F. W. Woolworth Company, BA, PricewaterhouseCoopers, MBA, Miller Brewing Company, U.S. Securities and Exchange Commission, TheNEWS magazine, The Coca-Cola Company, Digital, Linfield University, Growth, Atmos, Leadership, Omnichannel, Commercial, Culture, University of Michigan, BJ, BJ's Wholesale Club, Georgetown University, Business development, Retail, Management

NEW YORK, Nov.18,2021 /PRNewswire/ --Foot Locker, Inc. (NYSE: FL) ("Foot Locker" or the "Company"),theNew York-basedspecialtyathletic retailer,today announced organizational enhancements to advance its long-term global growth and power its omni-channel ecosystem.

Key Points: 
  • NEW YORK, Nov.18,2021 /PRNewswire/ --Foot Locker, Inc. (NYSE: FL) ("Foot Locker" or the "Company"),theNew York-basedspecialtyathletic retailer,today announced organizational enhancements to advance its long-term global growth and power its omni-channel ecosystem.
  • I look forward to continuing to work closely with these seasoned leaders as we advance Foot Locker's strategy and global growth agenda."
  • Foot Locker's new leadership appointments and organizational enhancements underscore its focus on aligning its operations and commercial teams to drive organizational productivity.
  • Susie Kuhn joined Foot Locker, Inc. in February 2020 as Senior Vice President, General Manager, Foot Locker Europe.

Cummins Inc. Names Steph Disher Vice President – Cummins Filtration

Retrieved on: 
Venerdì, Novembre 12, 2021
Engineering, Oil, Gas, Manufacturing, Alternative Energy, Energy, Other Manufacturing, University, Master of Business Administration, Directorate of Operations (CIA), Filtration, Leadership, Education, BP, Commerce, Multimedia, CMI, Natural gas, Community, TEC, University of Western Sydney Law Review, Environment, Solution, PRIDE, Business administration, NYSE, University of Melbourne, Management

Today, Cummins Inc. (NYSE: CMI) announced that Steph Disher has been named Vice President Cummins Filtration, effective November 15.

Key Points: 
  • Today, Cummins Inc. (NYSE: CMI) announced that Steph Disher has been named Vice President Cummins Filtration, effective November 15.
  • View the full release here: https://www.businesswire.com/news/home/20211112005828/en/
    Disher began leading the Filtration business in August 2020, navigating the business during the global pandemic and related ongoing supply chain constraints.
  • Disher has led the business as Cummins explores strategic alternatives for it, a move that was announced as part the Companys second quarter 2021 results.
  • Disher entered Cummins as Director of Finance for the South Pacific region in Australia in 2013.

Pepperstone Group is pleased to announce the appointment of David Shafer to serve as a board advisor

Retrieved on: 
Venerdì, Ottobre 29, 2021
Cyprus Securities and Exchange Commission, Australian Securities and Investments Commission, CMA, Commerce, CFO, Chartered Financial Analyst, Securities commission, CFD, Kogan.com, Dubai Financial Services Authority, Pedigree, Federal Financial Supervisory Authority, Capital market, Capital Markets Authority of Kenya, Investment, Federal, FCA, University, Bachelor of Commerce, UK, University of Melbourne, Growth, COO, Securities and Exchange Commission, SCB, DFSA, ASIC, Financial adviser

Prior to joining Kogan.com, David was a Senior Associate lawyer at Arnold Bloch Leibler.

Key Points: 
  • Prior to joining Kogan.com, David was a Senior Associate lawyer at Arnold Bloch Leibler.
  • David holds a Bachelor of Law (Honours) and a Bachelor of Commerce from The University of Melbourne.
  • "We are pleased to formally welcome David to Pepperstone.
  • I have known David for a number of years and he is a highly intelligent and capable business leader.

Pepperstone Group is pleased to announce the appointment of David Shafer to serve as a board advisor

Retrieved on: 
Venerdì, Ottobre 29, 2021
Cyprus Securities and Exchange Commission, Australian Securities and Investments Commission, CMA, Commerce, CFO, Chartered Financial Analyst, Securities commission, CFD, Kogan.com, Dubai Financial Services Authority, Pedigree, Federal Financial Supervisory Authority, Capital market, Capital Markets Authority of Kenya, Investment, Federal, FCA, University, Bachelor of Commerce, UK, University of Melbourne, Growth, Multimedia, COO, Securities and Exchange Commission, SCB, DFSA, ASIC, Financial adviser

Prior to joining Kogan.com, David was a Senior Associate lawyer at Arnold Bloch Leibler.

Key Points: 
  • Prior to joining Kogan.com, David was a Senior Associate lawyer at Arnold Bloch Leibler.
  • David holds a Bachelor of Law (Honours) and a Bachelor of Commerce from The University of Melbourne.
  • "We are pleased to formally welcome David to Pepperstone.
  • I have known David for a number of years and he is a highly intelligent and capable business leader.

Cypherpunk Holdings Appoints Jeffrey Gao as President and Chief Executive Officer and Tony Guoga Executive Chairman

Retrieved on: 
Mercoledì, Ottobre 27, 2021
Politico, Industry, CSE, Kaplan Business School, Melbourne, Bachelor of Science, Time, European Parliament, OTC Markets Group, Forward-looking statement, University, Company, Investment, Phrase, Board, CEO, University of Melbourne, Growth, HODL, European, Privacy, News, Actuarial science, Monash University, Electricity, Director, Management, Online gambling

Tony Guoga, currently the Chief Executive Officer, has been appointed Executive Chairman.

Key Points: 
  • Tony Guoga, currently the Chief Executive Officer, has been appointed Executive Chairman.
  • Moe Adham, Director and Chief Investment Officer: "Jeffrey has the leadership track record and breadth of business experience we believe are critical to lead Cypherpunk.
  • Speaking on behalf of the board, we look forward to working closely with Jeffrey as Chief Executive Officer."
  • Tony has been an exemplary leader as Chief Executive Officer during his time with a steadfast commitment to building Cypherpunk's business.

Increased Dairy Intake in Nursing Home Residents Leads To 33% Reduced Risk of Fracture

Retrieved on: 
Mercoledì, Ottobre 27, 2021
Science, University, Research, Nutrient, Quality of life, RDN, Nursing, Yogurt, Hip, Milk, Dairy Australia, BMJ, Dietary Guidelines for Americans, Cheese, Muscle, Organization, Patient, Magnesium, Risk, Lead, Food, Aarhus University Hospital, Vitamin D, Ageing, Dairy Council of California, Dairy Farmers of Canada, Bone, Clinical trial, Injury, Public health, Health, Accident, Fracture, University of Melbourne, GLOBE, Incidence, Probiotic, Phosphorus, Student, Dietary supplement

Researchers from the University of Melbourne saw that increased intake of dairy foods was associated with a 33% reduced risk of fracture in nursing home residents, after just six months.

Key Points: 
  • Researchers from the University of Melbourne saw that increased intake of dairy foods was associated with a 33% reduced risk of fracture in nursing home residents, after just six months.
  • Over 7,000 nursing home residents in 60 nursing homes took part in the randomized control trial over a period of two years.
  • The other half increased dairy (milk, cheese, yogurt and skim milk powder) to 3.5 servings per day.
  • In addition to a 33% reduction in overall fracture risk, the researchers also observed that patients who increased their intake of dairy had a 46% reduction in hip fractures and an 11% reduction in falls.